Patents by Inventor Morihisa Saitoh

Morihisa Saitoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066047
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 29, 2024
    Inventors: MASATO YOSHIKAWA, MORIHISA SAITOH, TAISUKE KATO, YAYOI NAKAYAMA, TOMOHIRO SEKI, YASUO NAKAGAWA, YUSUKE TOMINARI, MASAKI SETO, YUSUKE SASAKI, MASANORI OKANIWA, TSUNEO ODA, AKITO SHIBUYA, KOSUKE HIDAKA, ZENYU SHIOKAWA, SHUMPEI MURATA, ATSUTOSHI OKABE, YOSHIHISA NAKADA, MICHIYO MOCHIZUKI, BRIAN SCOTT FREEZE, TAISUKE TAWARAISHI, YASUFUMI WADA, PAUL D. GREENSPAN
  • Patent number: 11666594
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 6, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • Publication number: 20210137962
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 13, 2021
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
  • Patent number: 10980825
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 20, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Yoshihisa Nakada, Michiyo Mochizuki
  • Publication number: 20210106607
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • Patent number: 10787462
    Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: September 29, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takatoshi Yogo, Masato Yoshikawa, Morihisa Saitoh, Taisuke Katoh, Tomohiro Seki, Yoshihisa Nakada
  • Patent number: 10738004
    Abstract: Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 11, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Nobuyuki Negoro, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
  • Publication number: 20190233370
    Abstract: The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI). The present invention relates to ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl)-3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: August 1, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Publication number: 20190192549
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 27, 2019
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • Publication number: 20180319819
    Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 8, 2018
    Inventors: Takatoshi YOGO, Masato YOSHIKAWA, Morihisa SAITOH, Taisuke KATOH, Tomohiro SEKI, Yoshihisa NAKADA
  • Publication number: 20180118708
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Application
    Filed: May 6, 2016
    Publication date: May 3, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Patent number: 9828357
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro, Taisuke Katoh, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
  • Patent number: 9611244
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 4, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Publication number: 20170066737
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Patent number: 9533966
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Publication number: 20160326133
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Application
    Filed: June 7, 2016
    Publication date: November 10, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Publication number: 20160326102
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Publication number: 20160159773
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 9, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Morihisa Saitoh, Takatoshi Yogo, Taku Kamei, Norihito Tokunaga, Yusuke Ohba, Takafumi Yukawa
  • Patent number: 9187453
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: November 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Tsukamoto, Yusuke Ohba, Takafumi Yukawa, Hiroyuki Nagamiya, Taku Kamei, Norihito Tokunaga, Morihisa Saitoh
  • Publication number: 20150094296
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 2, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Tsukamoto, Yusuke Ohba, Takafumi Yukawa, Hiroyuki Nagamiya, Taku Kamei, Norihito Tokunaga, Morihisa Saitoh, Atsutoshi Okabe